He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck has also decided to end the favezelimab clinical development program
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Final decision from the European Commission is anticipated within the coming months
First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
